{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:56:57Z","timestamp":1762369017181,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jiac.2025.102734","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:17:03Z","timestamp":1747423023000},"page":"102734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir\/emtricitabine\/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-873X","authenticated-orcid":false,"given":"Eisuke","family":"Adachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yokomaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Shirasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumi","family":"Wakatabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Chamay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Sutherland-Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimgaile","family":"Urbaityte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102734_bib1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3 Suppl 2","key":"10.1016\/j.jiac.2025.102734_bib2","article-title":"Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis","volume":"16","author":"Katz","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jiac.2025.102734_bib3","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks","volume":"24","author":"Murray","year":"2020","journal-title":"AIDS Behav"},{"year":"2024","series-title":"ViiV Healthcare","key":"10.1016\/j.jiac.2025.102734_bib4"},{"journal-title":"Anti-HIV Treatment Guidelines","article-title":"Labor and welfare administration promotion survey project subsidy AIDS countermeasures policy research project","year":"2024","key":"10.1016\/j.jiac.2025.102734_bib6"},{"key":"10.1016\/j.jiac.2025.102734_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2025.102734_bib8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2025.102734_bib9","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s10461-021-03515-2","article-title":"Factors associated with treatment satisfaction among people living with HIV in Japan and other selected countries: examination of the intertwined roles of medication, patient, and provider characteristics","volume":"26","author":"Koga","year":"2022","journal-title":"AIDS Behav"},{"key":"10.1016\/j.jiac.2025.102734_bib11","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2025.102734_bib12","unstructured":"Oka S, Shirasaka T, Yokomaku Y, Orkin C, Arast\u00e9h K, G\u00f3rgolas H\u00e9rnandez-Mora M, et al. Long-acting cabotegravir + rilpivirine for HIV-1 maintenance therapy: 48 week results from the FLAIR study in participants from Japan. Presented at: 35th annual meeting of the Japanese society for AIDS research; November 21-23, 2021; Tokyo, Japan."},{"key":"10.1016\/j.jiac.2025.102734_bib13","first-page":"2023","article-title":"Cabotegravir + rilpivirine long-acting outcomes by sex at birth, age, race, and ethnicity: a subgroup analysis of the phase 3b SOLAR study","volume":"8-10","author":"Eu","year":"2023","journal-title":"Presented at: asia-pacific AIDS & co-infections conference (APACC)"},{"key":"10.1016\/j.jiac.2025.102734_bib14","series-title":"Presented at: asia-pacific AIDS & co-infections conference (APACC) 2020. October 15-17","article-title":"Pooled analysis of the efficacy, safety, and health outcomes following 48 weeks of long-acting cabotegravir and rilpivirine maintenance therapy for HIV-1 infection in phase 3 ATLAS and FLAIR studies: sub-analysis in Asian populations","author":"Choi","year":"2020"},{"key":"10.1016\/j.jiac.2025.102734_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/hiv.13588","article-title":"Asian participants' experience in phase 3\/3b studies of long-acting cabotegravir and rilpivirine: efficacy, safety, pharmacokinetic, and virological outcomes through week 96","volume":"25","author":"Oka","year":"2024","journal-title":"HIV Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2500131X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2500131X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:48:49Z","timestamp":1762368529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2500131X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1341321X2500131X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102734","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir\/emtricitabine\/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102734"}}